{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["N-aryl-2-trifluoromethyl-quinazoline", "Antiproliferative", "Werner helicase"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38739229", "DateRevised": {"Year": "2024", "Month": "05", "Day": "13"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1007/s11030-024-10844-6"], "ArticleDate": [{"Year": "2024", "Month": "05", "Day": "13"}], "Journal": {"ISSN": "1573-501X", "JournalIssue": {"PubDate": {"Year": "2024", "Month": "May", "Day": "13"}}, "Title": "Molecular diversity", "ISOAbbreviation": "Mol Divers"}, "ArticleTitle": "Design and synthesis of N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as potential Werner-dependent antiproliferative agents.", "Abstract": {"AbstractText": ["To discover new Werner (WRN) helicase inhibitors, a series of N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives were designed and synthesized through a structural optimization strategy, and the anticancer activities of 25 new target compounds against PC3, K562, and HeLa cell lines were evaluated by the MTT assay. Some of these compounds exhibited excellent inhibitory activity against three different cancer cell lines. Compounds 6a, 8i, and 13a showed better antiproliferative activity against K562 cells, with IC<sub>50</sub> values of 3871.5, 613.6 and 134.7\u00a0nM, respectively, than did paclitaxel (35.6\u00a0nM), doxorubicin (2689.0\u00a0nM), and NSC 617145 (20.3\u00a0nM). To further verify whether the antiproliferative activity of these compounds is dependent on WRN, PC3 cells overexpressing WRN (PC3-WRN) were constructed to further study their antiproliferative potency in vitro, and the inhibition ratio and IC<sub>20</sub> values showed that compounds 6a, 8i, and 13a were more sensitive to PC3-WRN than were the control group cells (PC3-NC). The IC<sub>20</sub> ratios of compounds 6a, 8i, and 13a to PC3-NC and PC3-WRN were 94.3, 153.4 and 505.5, respectively. According to the docking results, the compounds 6a, 8i, and 13a overlapped well with the binding pocket of 6YHR. Further study demonstrated that among the tested compounds, 13a was the most sensitive to PC3-WRN. In summary, our research identified a series of N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as potential WRN-dependent anticancer agents."], "CopyrightInformation": "\u00a9 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Li", "ForeName": "Huimin", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Yu", "ForeName": "Jia", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Yu", "ForeName": "Gang", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Cheng", "ForeName": "Sha", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Wu", "ForeName": "Hui", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Wei", "ForeName": "Jiaomei", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China."}], "LastName": "You", "ForeName": "Chang", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Liu", "ForeName": "Kun", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China."}], "LastName": "Wang", "ForeName": "Menghan", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China."}], "LastName": "Meng", "ForeName": "Xueling", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. xgc0707@163.com."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China. xgc0707@163.com."}], "LastName": "Xu", "ForeName": "Guangcan", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. luo_heng@gmc.edu.cn."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China. luo_heng@gmc.edu.cn."}], "LastName": "Luo", "ForeName": "Heng", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550014, China. bixue_xu@126.com."}, {"Identifier": [], "Affiliation": "Natural Products Research Center of Guizhou Province, Guiyang, 550014, China. bixue_xu@126.com."}], "LastName": "Xu", "ForeName": "Bixue", "Initials": "B"}], "GrantList": [{"GrantID": "No. 21NSFCP42", "Agency": "Natural Science Foundation of Guizhou Medical University", "Country": ""}, {"GrantID": "No. 22NSFCP24", "Agency": "Natural Science Foundation of Guizhou Medical University", "Country": ""}, {"GrantID": "No. QKHJC-ZK[2021]YB07", "Agency": "Natural Science Foundation of Guizhou province", "Country": ""}, {"GrantID": "No. QKHJC-ZK[2022]ZD031", "Agency": "Natural Science Foundation of Guizhou province", "Country": ""}, {"GrantID": "No. QKHZC [2023]YB241", "Agency": "The Science and Technology Planning Project of Guizhou Province", "Country": ""}, {"GrantID": "No. QKHPTRC-GCC[2022]034-1", "Agency": "Guizhou province \"Hundred\" level innovative talent training project", "Country": ""}, {"GrantID": "82260675", "Agency": "the National Natural Science Foundations of China", "Country": ""}, {"GrantID": "No. QKHPTRC[2016]5678", "Agency": "the Department of Science and Technology of Guizhou Province", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Mol Divers", "NlmUniqueID": "9516534", "ISSNLinking": "1381-1991"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Pearl LH, Schierz AC, Ward SE et al (2015) Therapeutic opportunities within the DNA damage response. Nat Rev Cancer 15:166\u2013180. https://doi.org/10.1038/nrc3891", "ArticleIdList": ["10.1038/nrc3891", "25709118"]}, {"Citation": "Tubbs A, Nussenzweig A (2017) Endogenous DNA damage as a source of genomic instability in cancer. Cell 168:644\u2013656. https://doi.org/10.1016/j.cell.2017.01.002", "ArticleIdList": ["10.1016/j.cell.2017.01.002", "28187286", "6591730"]}, {"Citation": "Wang M, Chen S, Ao D (2021) Targeting DNA repair pathway in cancer: mechanisms and clinical application. MedComm 2:654\u2013691. https://doi.org/10.1002/mco2.103", "ArticleIdList": ["10.1002/mco2.103", "34977872", "8706759"]}, {"Citation": "Laghi L, Bianchi P, Malesci A (2008) Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 27:6313\u20136321. https://doi.org/10.1038/onc.2008.217", "ArticleIdList": ["10.1038/onc.2008.217", "18679418"]}, {"Citation": "Vukovi\u0107 \u0110erfi K, Salar A, Cacev T et al (2023) EMAST type of microsatellite instability-a distinct entity or blurred overlap between stable and MSI tumors. Genes (Basel) 14:1474. https://doi.org/10.3390/genes14071474", "ArticleIdList": ["10.3390/genes14071474", "37510378"]}, {"Citation": "van Wietmarschen N, Sridharan S, Nathan WJ et al (2020) Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature 586:292\u2013298. https://doi.org/10.1038/s41586-020-2769-8", "ArticleIdList": ["10.1038/s41586-020-2769-8", "32999459", "8916167"]}, {"Citation": "Ye T, Lin A, Qiu Z et al (2023) Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity. iScience 26:107045. https://doi.org/10.1016/j.isci.2023.107045", "ArticleIdList": ["10.1016/j.isci.2023.107045", "37448561", "10336167"]}, {"Citation": "Saydam N, Kanagaraj R, Dietschy T et al (2007) Physical and functional interactions between Werner syndrome helicase and mismatch-repair initiation factors. Nucleic Acids Res 35:5706\u20135716. https://doi.org/10.1093/nar/gkm500", "ArticleIdList": ["10.1093/nar/gkm500", "17715146", "2034464"]}, {"Citation": "Datta A, Dhar S, Awate S et al (2021) Synthetic lethal interactions of RECQ helicases. Trends Cancer 7:146\u2013161. https://doi.org/10.1016/j.trecan.2020.09.001", "ArticleIdList": ["10.1016/j.trecan.2020.09.001", "33041245"]}, {"Citation": "Chan EM, Shibue T, McFarland JM et al (2019) WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568:551\u2013556. https://doi.org/10.1038/s41586-019-1102-x", "ArticleIdList": ["10.1038/s41586-019-1102-x", "30971823", "6580861"]}, {"Citation": "Picco G, Cattaneo CM, van Vliet EJ et al (2021) Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy. Cancer Discov 11:1923\u20131937. https://doi.org/10.1158/2159-8290.CD-20-1508", "ArticleIdList": ["10.1158/2159-8290.CD-20-1508", "33837064"]}, {"Citation": "Hao S, Tong J, Jha A et al (2022) Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer. Proc Natl Acad Sci USA 119:e2211775119. https://doi.org/10.1073/pnas.2211775119", "ArticleIdList": ["10.1073/pnas.2211775119", "36508676", "9907101"]}, {"Citation": "Parker MJ, Lee H, Yao S et al (2023) Identification of 2-sulfonyl/sulfonamide pyrimidines as covalent inhibitors of WRN using a multiplexed high-throughput screening assay. Biochemistry 62:2147\u20132160. https://doi.org/10.1021/acs.biochem.2c00599", "ArticleIdList": ["10.1021/acs.biochem.2c00599", "37403936"]}, {"Citation": "Aggarwal M, Banerjee T, Sommers JA et al (2013) Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway. Cancer Res 73:5497\u20135507. https://doi.org/10.1158/0008-5472.CAN-12-2975", "ArticleIdList": ["10.1158/0008-5472.CAN-12-2975", "23867477", "3766423"]}, {"Citation": "Aggarwal M, Sommers JA, Shoemaker RH et al (2011) Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci USA 108:1525\u20131530. https://doi.org/10.1073/pnas.1006423108", "ArticleIdList": ["10.1073/pnas.1006423108", "21220316", "3029756"]}, {"Citation": "Moles R, Bai X, Chaib-Mezrag H et al (2016) WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J Hematol Oncol 9:121. https://doi.org/10.1186/s13045-016-0352-4", "ArticleIdList": ["10.1186/s13045-016-0352-4", "27829440", "5103433"]}, {"Citation": "Sommers JA, Kulikowicz T, Croteau DL et al (2019) A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN). PLoS ONE 14:e0210525. https://doi.org/10.1371/journal.pone.0210525", "ArticleIdList": ["10.1371/journal.pone.0210525", "30625228", "6326523"]}, {"Citation": "Auti PS, George G, Paul AT et al (2020) Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv 10:41353\u201341392. https://doi.org/10.1039/d0ra06642g", "ArticleIdList": ["10.1039/d0ra06642g", "35516563", "9057921"]}, {"Citation": "Bhatia P, Sharma V, Alam O et al (2020) Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015\u20132019). Eur J Med Chem 204:112640. https://doi.org/10.1016/j.ejmech.2020.112640", "ArticleIdList": ["10.1016/j.ejmech.2020.112640", "32739648"]}, {"Citation": "Plescia F, Maggio B, Daidone G et al (2021) 4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: a promising scaffold toward bioactive molecules. Eur J Med Chem 213:113070. https://doi.org/10.1016/j.ejmech.2020.113070", "ArticleIdList": ["10.1016/j.ejmech.2020.113070", "33309162"]}, {"Citation": "Wang X, Guan F, Ohkoshi E et al (2014) Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site. J Med Chem 57:1390\u20131402. https://doi.org/10.1021/jm4016526", "ArticleIdList": ["10.1021/jm4016526", "24502232", "3983391"]}, {"Citation": "Ravez S, Castillo-Aguilera O, Depreux P et al (2015) Quinazoline derivatives as anticancer drugs: a patent review (2011-present). Expert Opin Ther Pat 25:789\u2013804. https://doi.org/10.1517/13543776.2015.1039512", "ArticleIdList": ["10.1517/13543776.2015.1039512", "25910402"]}, {"Citation": "Hosomi Y, Morita S, Sugawara S et al (2020) Gefitinib alone versus Gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38:115\u2013123. https://doi.org/10.1200/jco.19.01488", "ArticleIdList": ["10.1200/jco.19.01488", "31682542"]}, {"Citation": "Yang Z, Hackshaw A, Feng Q et al (2017) Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer 140:2805\u20132819. https://doi.org/10.1002/ijc.30691", "ArticleIdList": ["10.1002/ijc.30691", "28295308"]}, {"Citation": "Laskin J, Liu S, Tolba K et al (2020) NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol 31:1693\u20131703. https://doi.org/10.1016/j.annonc.2020.08.2335", "ArticleIdList": ["10.1016/j.annonc.2020.08.2335", "32916265"]}, {"Citation": "Shirley M (2018) Dacomitinib: first global approval. Drugs 78:1947\u20131953. https://doi.org/10.1007/s40265-018-1028-x", "ArticleIdList": ["10.1007/s40265-018-1028-x", "30506139"]}, {"Citation": "Manevski N, King L, Pitt W et al (2019) Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery. J Med Chem 62:10955\u201310994. https://doi.org/10.1021/acs.jmedchem.9b00875", "ArticleIdList": ["10.1021/acs.jmedchem.9b00875", "31385704"]}, {"Citation": "Liu K, Mo M, Yu G et al (2023) Discovery of novel 2-(trifluoromethyl)quinolin-4-amine derivatives as potent anticancer agents with microtubule polymerization inhibitory activity. Bioorg Chem 139:106727. https://doi.org/10.1016/j.bioorg.2023.106727", "ArticleIdList": ["10.1016/j.bioorg.2023.106727", "37451147"]}, {"Citation": "Jin X, Wang S, Zhao LM et al (2023) Development of fluorine-substituted NH<sub>2</sub>-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: boosting the safety and metabolic stability. Acta Pharm Sin B 13:1192\u20131203. https://doi.org/10.1016/j.apsb.2022.08.017", "ArticleIdList": ["10.1016/j.apsb.2022.08.017", "36970200"]}, {"Citation": "Johnson BM, Shu Y, Zhuo X et al (2020) Metabolic and pharmaceutical aspects of fluorinated compounds. J Med Chem 63:6315\u20136386. https://doi.org/10.1021/acs.jmedchem.9b01877", "ArticleIdList": ["10.1021/acs.jmedchem.9b01877", "32182061"]}, {"Citation": "Jayanetti K, Takemura K, Bendale H et al (2023) Recent advances in the strategic incorporation of fluorine into new-generation taxoid anticancer agents\u2606. J Fluorine Chem 267:110106. https://doi.org/10.1016/j.jfluchem.2023.110106", "ArticleIdList": ["10.1016/j.jfluchem.2023.110106"]}, {"Citation": "Oguz M (2022) Synthesis and anticancer activity of new p-tertbutylcalix[4]arenes integrated with trifluoromethyl aniline groups against several cell lines. Tetrahedron 116:132816. https://doi.org/10.1016/j.tet.2022.132816", "ArticleIdList": ["10.1016/j.tet.2022.132816"]}, {"Citation": "Meanwell NA (2018) Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. J Med Chem 61:5822\u20135880. https://doi.org/10.1021/acs.jmedchem.7b01788", "ArticleIdList": ["10.1021/acs.jmedchem.7b01788", "29400967"]}, {"Citation": "Dol\u0161ak A, \u0160vajger U, Le\u0161nik S et al (2019) Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/quinazoline-4-amine scaffolds. Eur J Med Chem 179:109\u2013122. https://doi.org/10.1016/j.ejmech.2019.06.030", "ArticleIdList": ["10.1016/j.ejmech.2019.06.030", "31247373"]}]}], "History": [{"Year": "2024", "Month": "1", "Day": "4"}, {"Year": "2024", "Month": "3", "Day": "8"}, {"Year": "2024", "Month": "5", "Day": "13", "Hour": "12", "Minute": "53"}, {"Year": "2024", "Month": "5", "Day": "13", "Hour": "12", "Minute": "53"}, {"Year": "2024", "Month": "5", "Day": "13", "Hour": "11", "Minute": "7"}], "PublicationStatus": "aheadofprint", "ArticleIdList": ["38739229", "10.1007/s11030-024-10844-6", "10.1007/s11030-024-10844-6"]}}]}